B. Metzler seel. Sohn & Co. AG Purchases Shares of 21,870 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 21,870 shares of the medical device company's stock, valued at approximately $788,000.

A number of other hedge funds also recently added to or reduced their stakes in TNDM. Arizona State Retirement System raised its stake in shares of Tandem Diabetes Care by 1.9% during the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock worth $683,000 after purchasing an additional 362 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after acquiring an additional 535 shares during the period. AlphaQuest LLC lifted its stake in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Tandem Diabetes Care by 4.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,664 shares of the medical device company's stock valued at $664,000 after acquiring an additional 704 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its stake in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after acquiring an additional 748 shares during the period.

Remove Ads

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded up $0.06 during mid-day trading on Tuesday, hitting $16.91. 321,213 shares of the company were exchanged, compared to its average volume of 1,474,471. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The business's 50 day simple moving average is $25.96 and its two-hundred day simple moving average is $31.89. The company has a market capitalization of $1.12 billion, a P/E ratio of -8.79 and a beta of 1.52.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on TNDM shares. Royal Bank of Canada lowered their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Robert W. Baird decreased their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th. Morgan Stanley cut Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Eight investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.38.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by company insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.